Original ArticlesA Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015)
Under an Elsevier user license
open archive
Key words
Non–small-cell lung cancer
Biomarker
Bevacizumab
Vascular endothelial growth factor
Cited by (0)
Disclosure: Tony Mok is a consultant for, and has received honorarium from, AstraZeneca, Eli Lilly, Merck Serono, Eisai, BMS, Biogene, AVEO, Pfizer, Taiho, Boehringer Ingelheim, GSK Biologicals, and has received research funding from AstraZeneca. Celine Pallaud, Magalie Hilton, Paul Delmar and Venice Archer are employees of F. Hoffmann-La Roche Ltd. Martin Reck is a consultant for, and has received honorarium from, BMS, Daiichi Sankyo and AstraZeneca. Chong-Jen Yu, Barna Szima, Sergey Orlov, Erzsebet Juhasz, Vera Gorbunova and Olga Burdaeva have no conflicts of interest to declare.
Copyright © 2014 International Association for the Study of Lung Cancer. All rights reserved.